CN117298104B - Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 - Google Patents
Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 Download PDFInfo
- Publication number
- CN117298104B CN117298104B CN202311615721.9A CN202311615721A CN117298104B CN 117298104 B CN117298104 B CN 117298104B CN 202311615721 A CN202311615721 A CN 202311615721A CN 117298104 B CN117298104 B CN 117298104B
- Authority
- CN
- China
- Prior art keywords
- mycn
- elovl6
- amplified
- neuroblastoma
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010029260 Neuroblastoma Diseases 0.000 title claims abstract description 52
- 101150022024 MYCN gene Proteins 0.000 title claims abstract description 32
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 title claims abstract description 32
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 title claims abstract description 30
- 108700012912 MYCN Proteins 0.000 title claims abstract description 29
- XLEVMSDNWOWFNX-UHFFFAOYSA-N 6,6-dimethyl-3-[5-methyl-3-oxo-2-[4-(trifluoromethoxy)phenyl]-1h-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione Chemical compound O=C1C(C2(C3=C(CC(C)(C)CC3=O)N(C2=O)C=2C=CC=CC=2)C(F)(F)F)=C(C)NN1C1=CC=C(OC(F)(F)F)C=C1 XLEVMSDNWOWFNX-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 15
- 150000003384 small molecules Chemical class 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000086 high toxicity Toxicity 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 238000001514 detection method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003235 crystal violet staining Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 101710087370 N-myc protein Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000012191 childhood neoplasm Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100011517 Drosophila melanogaster ELOVL gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000984033 Homo sapiens Protein lin-28 homolog B Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100025459 Protein lin-28 homolog B Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了ELOVL6‑IN‑2在制备MYCN扩增型神经母细胞瘤药物中的应用,属于生物医药技术领域。本发明提供的小分子抑制剂ELOVL6‑IN‑2可抑制MYCN扩增型神经母细胞瘤的活力,对正常细胞和MYCN非扩增的NB细胞抑制效果不显著,说明其具有抑制特异性,对高危NB患儿治疗具有重要意义。本发明提供的ELOVL6‑IN‑2新应用解决了现有技术中MYCN扩增型高危神经母细胞瘤靶向药疗效欠佳、毒性较大等问题,为MYCN扩增型神经母细胞瘤的治疗提供了一种新的途径,具有高特异性和针对其他细胞类型副作用小的优点。
Description
技术领域
本发明涉及生物医药技术领域,尤其涉及ELOVL6-IN-2在制备MYCN扩增型神经母细胞瘤药物中的应用。
背景技术
MYCN基因属于MYC家族成员,编码转录因子N-Myc,通过转录下游系列靶基因,调控细胞增殖、分化及凋亡等重要生物学过程。研究发现MYCN基因在多种肿瘤存在扩增,如神经母细胞瘤、视网膜母细胞瘤、肺癌、肾癌等。
神经母细胞瘤(Neuroblastoma,NB)是儿童期最常见的颅外恶性实体肿瘤,发病率占儿童肿瘤的8-10%,死亡率约占所有儿童肿瘤的15%。高危NB患儿发病隐匿、恶性程度高、进展快,传统的“手术+放化疗”模式获益有限,多数患儿进展为难治性NB,5年生存率仅约50%。
临床研究表明,MYCN基因扩增约占高危NB患儿的40-50%,是高危NB的诊断金标准,但由于其蛋白质结构的特点,不易被小分子药物结合,目前被认为是“无药可靶”的蛋白,严重限制了高危NB的治疗效果。
目前新型反义寡核苷酸可通过靶向N-Myc蛋白质降解,从而抑制MYCN扩增型高危神经母细胞瘤的生长,但其疗效欠佳;有研究发现LIN28B和Aurora A激酶可调控N-Myc蛋白质稳定性,且Aurora A抑制剂可在小鼠水平抑制MYCN扩增型高危NB的发生,但由于高剂量抑制剂毒性较大导致其在临床试验中疗效受限。
寻找特异、精准的治疗靶点和药物,是提高MYCN扩增高危NB患儿治愈率和长期生存率、改善整体NB患儿预后的前提,也是临床治疗亟需解决的问题。中国专利CN110541029B公开了一种乙醛脱氢酶18A1基因及其编码产物在MYCN扩增神经母细胞瘤中的应用,可以作为MYCN扩增神经母细胞瘤的治疗及药物筛选靶点,对MYCN扩增神经母细胞瘤治疗及药物筛选提供了新的思路;同时还可以作为MYCN扩增神经母细胞瘤的诊断标志物,可用于MYCN扩增神经母细胞瘤的早期诊断和预后监测,对MYCN扩增神经母细胞瘤的治疗和诊断具有重要的临床意义。但是并未提供有效的特异性治疗手段。
发明内容
本发明的目的在于提供ELOVL6-IN-2在制备MYCN扩增型神经母细胞瘤药物中的应用,为MYCN扩增型神经母细胞瘤的治疗提供了一种新的途径。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了ELOVL6-IN-2在制备治疗或辅助治疗MYCN扩增型神经母细胞瘤药物中的应用。
本发明还提供了ELOVL6-IN-2在制备MYCN扩增型神经母细胞瘤细胞系SK-N-BE(2)活性抑制剂中的应用。
优选的,所述ELOVL6-IN-2的应用浓度在59.6nM以上。
本发明还提供了ELOVL6-IN-2在制备MYCN扩增型神经母细胞瘤细胞系IMR-32活性抑制剂中的应用。
优选的,所述ELOVL6-IN-2的应用浓度在528.4nM以上。
本发明还提供了ELOVL6-IN-2在制备MYCN扩增型神经母细胞瘤细胞系KELLY活性抑制剂中的应用。
优选的,所述ELOVL6-IN-2的应用浓度在69.64nM以上。
本发明还提供了一种MYCN扩增型神经母细胞瘤特异性抑制剂,所述特异性抑制剂以ELOVL6-IN-2作为活性成分,所述特异性抑制剂为药物或药物组合物。
优选的,所述特异性抑制剂的剂型为散剂、片剂、颗粒剂、胶囊剂、溶液剂、乳剂、混悬剂、注射剂、喷雾剂、气雾剂或粉雾剂。
本发明的有益效果:
本发明提供了小分子抑制剂ELOVL6-IN-2可抑制MYCN扩增型神经母细胞瘤的活力,对正常细胞和MYCN非扩增的NB细胞抑制效果不显著,说明其具有抑制特异性,对高危NB患儿治疗具有重要意义。本发明提供的方案突破了现有小分子抑制剂针对MYCN扩增NB细胞的特异性差,且对正常细胞的毒性大这一弊端,具有高特异性和针对其他细胞类型副作用小的优点。
附图说明
图1为ELOVL6-IN-2的结构式;
图2为小分子抑制剂ELOVL6-IN-2特异性抑制MYCN扩增型NB细胞活力的检测结果图,其中A为MYCN扩增型NB细胞系检测结果;B为MYCN不扩增型NB细胞系检测结果;C为正常细胞系检测结果;
图3为显微镜明场和结晶紫染色后的细胞密度和状态图。
具体实施方式
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
小分子抑制剂ELOVL6-IN-2,分子式C28H23F6N3O4,结构式如图1所示。
选取3种MYCN扩增型神经母细胞瘤细胞系:
SK-N-BE(2)、IMR-32和KELLY。
3种MYCN不扩增型神经母细胞瘤细胞系:
SK-N-AS、SH-SY5Y和SK-N-SH。
3种MYCN不扩增的正常细胞系:
人胚肾细胞系HEK293、人胚肺成纤维细胞IMR90和人视网膜色素上皮细胞HTERTRPE-1。
第一天:将1×10^3个细胞接种至96孔板中;
第二天:更换新的DMEM完全培养基,并在培养基中加入小分子抑制剂ELOVL6-IN-2,使ELOVL6-IN-2终浓度分别为0、10、10^2、10^3、10^4、10^5 nM,每组3个复孔,处理72小时。
拍摄明场下细胞状态,利用结晶紫染色观察细胞密度,利用CellTiter-Glo®Luminescent Cell Viability Assay试剂盒,检测细胞活力,结果如图2所示,显微镜明场和结晶紫染色后的细胞密度和状态结果如图3所示。
检测结果显示,小分子抑制剂ELOVL6-IN-2对MYCN扩增型NB细胞的半抑制浓度(IC50)分别为59.6 nM、528.4 nM和69.64 nM;
小分子抑制剂ELOVL6-IN-2对MYCN不扩增型NB细胞的IC50分别为178612 nM、12872nM和70522 nM;
小分子抑制剂ELOVL6-IN-2对正常细胞的IC50分别为157531 nM、1450337655 nM和6174292 nM。
图3中,通过显微镜明场和结晶紫检测发现,同一种浓度的小分子抑制剂ELOVL6-IN-2处理后,SK-N-BE(2)的细胞密度显著小于SH-SY5Y。
由结果可知,小分子抑制剂ELOVL6-IN-2针对MYCN扩增型NB细胞的药物处理浓度显著小于正常细胞和MYCN不扩增型NB细胞,说明该抑制剂可特异性抑制MYCN扩增型NB细胞的活力,对正常细胞和MYCN不扩增的NB细胞抑制效果不显著。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.化合物ELOVL6-IN-2在制备治疗MYCN扩增型神经母细胞瘤的药物中的应用;
所述化合物ELOVL6-IN-2的结构式如下式所示:
。
2.根据权利要求1所述的应用,其特征在于,所述MYCN扩增型神经母细胞瘤为SK-N-BE2。
3.根据权利要求1所述的应用,其特征在于,所述MYCN扩增型神经母细胞瘤为IMR-32。
4.根据权利要求1所述的应用,其特征在于,所述MYCN扩增型神经母细胞瘤为KELLY。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311615721.9A CN117298104B (zh) | 2023-11-30 | 2023-11-30 | Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311615721.9A CN117298104B (zh) | 2023-11-30 | 2023-11-30 | Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117298104A CN117298104A (zh) | 2023-12-29 |
CN117298104B true CN117298104B (zh) | 2024-03-12 |
Family
ID=89285149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311615721.9A Active CN117298104B (zh) | 2023-11-30 | 2023-11-30 | Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117298104B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117568347B (zh) * | 2024-01-15 | 2024-04-02 | 首都医科大学附属北京儿童医院 | Ppef1作为神经母细胞瘤药物靶点的应用 |
CN117582506B (zh) * | 2024-01-17 | 2024-04-02 | 首都医科大学附属北京儿童医院 | 一种跨膜蛋白tmeff1抑制剂在制备治疗神经母细胞瘤药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015074643A (ja) * | 2013-10-11 | 2015-04-20 | 独立行政法人国立がん研究センター | 神経芽腫治療剤 |
CN110538179A (zh) * | 2018-05-29 | 2019-12-06 | 余时沧 | Yg1702在制备aldh18a1特异性抑制剂中的应用 |
-
2023
- 2023-11-30 CN CN202311615721.9A patent/CN117298104B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015074643A (ja) * | 2013-10-11 | 2015-04-20 | 独立行政法人国立がん研究センター | 神経芽腫治療剤 |
CN110538179A (zh) * | 2018-05-29 | 2019-12-06 | 余时沧 | Yg1702在制备aldh18a1特异性抑制剂中的应用 |
Non-Patent Citations (3)
Title |
---|
"Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets";Haiwei Wang等;《BMC Pediatrics》;第20卷(第1期);Haiwei Wang等 * |
"Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors";Toshiyuki Takahashi等;《Journal of Medicinal Chemistry》;第52卷(第10期);第3142-3145页 * |
Toshiyuki Takahashi等."Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors".《Journal of Medicinal Chemistry》.2009,第52卷(第10期),第3142-3145页. * |
Also Published As
Publication number | Publication date |
---|---|
CN117298104A (zh) | 2023-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117298104B (zh) | Elovl6-in-2在制备mycn扩增型神经母细胞瘤药物中的应用 | |
US10959977B2 (en) | Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis | |
CN107184572B (zh) | 一种ape1抑制剂及其在制备用于治疗肿瘤和血管异常增生性疾病药物中的应用 | |
WO2020000704A1 (zh) | AMPK抑制剂Compound C在治疗肿瘤药物中的应用 | |
CN108014105B (zh) | Yd1701在制备治疗aldh1a3高表达肿瘤的药物中的应用 | |
WO2008106408A1 (en) | Treatment of cancer with bio and chemotherapy | |
CN113329745A (zh) | 一种有效抗恶性肿瘤的药物组合物及其应用 | |
CN113350325B (zh) | 二蒽酮类化合物在制备抗肿瘤药物中的应用 | |
CN112263578B (zh) | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 | |
CN114558141A (zh) | 降低胰腺癌细胞恶性表型的促进剂、药物组合及其用途 | |
CN105213366A (zh) | 藤黄酮化合物的医药用途及其药物组合物 | |
CN107661324B (zh) | 普罗帕酮在制备治疗食管癌药物中的应用 | |
KR102591642B1 (ko) | 종양 전이의 약물 치료를 위한 표적 및 이의 응용 | |
CN111973593A (zh) | 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途 | |
CN112043698A (zh) | 一组小分子药物在制备抑制肉瘤药物中的应用 | |
Du et al. | Cyclocarya paliurus polysaccharide inhibits glioma cell U251 proliferation, migration, and invasion and promotes apoptosis via the GSK3β/β-catenin signaling pathway | |
CN113117087A (zh) | 一种药物组合物及其应用 | |
CN105517558A (zh) | 土庄绣线菊提取物及其用途 | |
CN111281872B (zh) | 一种含阿法替尼的药物组合物及其应用 | |
JI et al. | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. | |
CN101502508B (zh) | 一种5-氧代-4-亚烯基-吡唑衍生物在制备抗肿瘤药物中的应用 | |
CN114641293B (zh) | 一种fgfr抑制剂的用途 | |
CN102341102A (zh) | 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途 | |
Sesink et al. | The AsiDNA™ decoy mimicking DSBs protects the normal tissue from radiation toxicity through a DNA-PK/p53/p21-dependent G1/S arrest | |
CN115607676A (zh) | 羧基苍术苷在制备抗肿瘤耐药性的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |